Maze Therapeutics, Inc. (MAZE) Misses Q2 EPS by 15c

Maze Therapeutics, Inc. (NASDAQ: MAZE) reported Q2 EPS of ($0.77), $0.15 worse than the analyst estimate of ($0.62).

For earnings history and earnings-related data on Maze Therapeutics, Inc. (MAZE) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Pentagon-Backed Oil Company Is Set to Vie for Chevron's Crown in Venezuela - WSJ
• NeuroSense posts narrower H1 loss, targets Canada drug filing by December